Ticker Hub
PLRX — AI Analysis & Sentiment
3 recent AI-generated analyses for PLRX. Sentiment and confidence insights updated continuously.
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
Pliant Therapeutics hit a key development milestone by dosing the first patient in its FORTIFY Phase 1b trial. This advances its lead oncology cand...
Apr 30, 2026Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics' updated Phase 1 data for PLN-101095 shows strong anti-tumor activity and tolerability, significantly de-risking this key pipel...
Apr 18, 2026Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics will present Phase 1 data for its oncology candidate PLN-101095 next month, potentially increasing investor interest and provid...
Mar 18, 2026